Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
AZN Stock Summary
Top 10 Correlated ETFs
AZN
In the News
AstraZeneca CEO Soriot on Pharmaceuticals in China
AstraZeneca CEO Pascal Soriot discusses the drugmaker's business strategy in China, the US “BIOSECURE Act,” and future deals and partnerships in China. He speaks with Stephen Engle on the sidelines of the BOAO forum.
Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts
In the most recent trading session, Astrazeneca (AZN) closed at $66.33, indicating a +0.71% shift from the previous trading day.
AstraZeneca's (AZN) Ultomiris Gets FDA Nod for New Indication
FDA approves AstraZeneca's (AZN) Ultomiris for AQP4 Ab+ NMOSD, making it the first and only long-acting C5 complement inhibitor approved for this rare neurological disease.
2 More Potential Biotech Buyout Targets
M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related products. The oncology space continues to be a hot and active area for deal volume, with global sales projected to reach $375 billion by 2027. Today, we profile two smaller oncology names that appear to be logical acquisitions for larger concerns that want to expand their oncology footprints.
3 Stagnating Blue-Chip Stocks Ready to Awaken and Soar
In my view, a sure-shot way of minting money from the markets is buying and holding with patience. Of course, the idea needs to be well-researched as a first step.
AstraZeneca (AZN) to Buy Fusion Pharmaceuticals for $2.4B
AstraZeneca (AZN) has offered to acquire Fusion for $21.00 per share in cash plus a contingent value (CV) payment of $3.00 per share.
AstraZeneca: Fusion acquisition will be a cost effective-investment that can improve cancer outcomes
Dr. Susan Galbraith, executive vice-president of oncology and R&D at AstraZeneca, discusses the healthcare giant's $2.4bn acquisition of Fusion Pharmaceuticals.
Astrazeneca (AZN) Rises Yet Lags Behind Market: Some Facts Worth Knowing
Astrazeneca (AZN) closed at $65.86 in the latest trading session, marking a +0.02% move from the prior day.
AstraZeneca (AZN) Follows Boehringer, to Cap Inhaler Cost in US
AstraZeneca (AZN) plans to lower the prices of its inhaled respiratory products to $35 per month in the United States. However, the company intends to start this in June 2024.
Biotech Stock Soars on AstraZeneca Buyout
Fusion Pharmaceuticals Inc (NASDAQ:FUSN) stock is skyrocketing today, after news that AstraZeneca (AZN) is acquiring the Canadian biotech company for $2.4 billion, or $21 per share.
AZN Financial details
AZN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 9.37 | 10.14 | 13.11 | 14.22 | 14.66 | |
Net income per share | 0.51 | 1.22 | 0.04 | 1.05 | 1.91 | |
Operating cash flow per share | 1.14 | 1.83 | 2.09 | 3.14 | 3.31 | |
Free cash flow per share | 0.2 | 0.84 | 1.32 | 2.32 | 2.1 | |
Cash per share | 2.39 | 3.04 | 2.24 | 2.05 | 1.88 | |
Book value per share | 5.04 | 5.95 | 13.76 | 11.87 | 12.53 | |
Tangible book value per share | -6.88 | -6.53 | -8.09 | -7.07 | -6.07 | |
Share holders equity per share | 5.04 | 5.95 | 13.76 | 11.87 | 12.53 | |
Interest debt per share | 7.56 | 8.26 | 11.24 | 9.8 | 9.67 | |
Market cap | 129.74B | 131.27B | 166.25B | 211.54B | 210.4B | |
Enterprise value | 142.59B | 143.82B | 190.7B | 234.6B | 233.18B | |
P/E ratio | 97.18 | 41.07 | 1.48K | 64.34 | 35.33 | |
Price to sales ratio | 5.32 | 4.93 | 4.44 | 4.77 | 4.59 | |
POCF ratio | 43.7 | 27.35 | 27.88 | 21.57 | 20.34 | |
PFCF ratio | 254.88 | 59.86 | 44.18 | 29.23 | 32.04 | |
P/B Ratio | 9.88 | 8.4 | 4.23 | 5.71 | 5.38 | |
PTB ratio | 9.88 | 8.4 | 4.23 | 5.71 | 5.38 | |
EV to sales | 5.85 | 5.4 | 5.1 | 5.29 | 5.09 | |
Enterprise value over EBITDA | 20.32 | 17.18 | 25.21 | 25.15 | 16.76 | |
EV to operating cash flow | 48.03 | 29.97 | 31.98 | 23.92 | 22.54 | |
EV to free cash flow | 280.14 | 65.58 | 50.68 | 32.42 | 35.51 | |
Earnings yield | 0.01 | 0.02 | 0 | 0.02 | 0.03 | |
Free cash flow yield | 0 | 0.02 | 0.02 | 0.03 | 0.03 | |
Debt to equity | 1.39 | 1.3 | 0.78 | 0.79 | 0.73 | |
Debt to assets | 0.3 | 0.31 | 0.29 | 0.3 | 0.28 | |
Net debt to EBITDA | 1.83 | 1.5 | 3.23 | 2.47 | 1.64 | |
Current ratio | 0.86 | 0.96 | 1.16 | 0.86 | 0.82 | |
Interest coverage | 2.04 | 3.95 | 0.81 | 2.79 | 5.16 | |
Income quality | 1.92 | 1.23 | -22.5 | 3.92 | 1.5 | |
Dividend Yield | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | |
Payout ratio | 2.69 | 1.12 | 34.43 | 1.33 | 0.75 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.24 | 0.23 | 0.26 | 0.22 | 0.24 | |
Intangibles to total assets | 0.53 | 0.49 | 0.59 | 0.61 | 0.57 | |
Capex to operating cash flow | -0.83 | -0.54 | -0.37 | -0.26 | -0.37 | |
Capex to revenue | -0.1 | -0.1 | -0.06 | -0.06 | -0.08 | |
Capex to depreciation | -0.65 | -0.83 | -0.34 | -0.47 | -0.77 | |
Stock based compensation to revenue | 0.01 | 0.01 | 0.02 | 0.01 | 0 | |
Graham number | 7.63 | 12.76 | 3.49 | 16.78 | 23.18 | |
ROIC | 0.07 | 0.11 | -0.01 | 0.07 | 0.1 | |
Return on tangible assets | 0.05 | 0.09 | 0 | 0.09 | 0.14 | |
Graham Net | -13.48 | -14.03 | -16.51 | -13.86 | -13.83 | |
Working capital | -2.55B | -763M | 3.65B | -3.7B | -5.49B | |
Tangible asset value | -17.91B | -17.15B | -23.1B | -22.07B | -18.97B | |
Net current asset value | -31.22B | -31.55B | -39.83B | -36.83B | -36.9B | |
Invested capital | 1.39 | 1.3 | 0.78 | 0.79 | 0.73 | |
Average receivables | 2.55B | 5.42B | 8.2B | 10.34B | 11.74B | |
Average payables | 13.41B | 14.89B | 17.36B | 18.99B | 11.15B | |
Average inventory | 3.04B | 3.61B | 6.5B | 6.84B | 5.06B | |
Days sales outstanding | 77.55 | 77.49 | 104.94 | 81.66 | 107.98 | |
Days payables outstanding | 1.04K | 1.09K | 555.79 | 560.86 | 144.23 | |
Days of inventory on hand | 236.83 | 277.18 | 263.63 | 138.42 | 239.45 | |
Receivables turnover | 4.71 | 4.71 | 3.48 | 4.47 | 3.38 | |
Payables turnover | 0.35 | 0.34 | 0.66 | 0.65 | 2.53 | |
Inventory turnover | 1.54 | 1.32 | 1.38 | 2.64 | 1.52 | |
ROE | 0.1 | 0.2 | 0 | 0.09 | 0.15 | |
Capex per share | -0.95 | -0.99 | -0.77 | -0.82 | -1.21 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 3.59 | 3.49 | 3.66 | 3.68 | 3.85 | |
Net income per share | 0.29 | 0.58 | 0.58 | 0.44 | 0.31 | |
Operating cash flow per share | 0.77 | 1 | 0.55 | 1 | 0.76 | |
Free cash flow per share | 0.59 | 0.53 | 0.4 | 0.72 | 0.46 | |
Cash per share | 2.05 | 2.07 | 1.86 | 1.64 | 1.88 | |
Book value per share | 11.88 | 11.47 | 11.98 | 11.92 | 12.54 | |
Tangible book value per share | -7.08 | -7.53 | -6.69 | -6.54 | -6.08 | |
Share holders equity per share | 11.88 | 11.47 | 11.98 | 11.92 | 12.54 | |
Interest debt per share | 9.49 | 10.21 | 9.7 | 9.28 | 9.3 | |
Market cap | 211.4B | 216.56B | 223.3B | 211.29B | 210.27B | |
Enterprise value | 234.47B | 241.83B | 247.47B | 234.99B | 233.05B | |
P/E ratio | 58.66 | 30.03 | 30.71 | 38.44 | 54.76 | |
Price to sales ratio | 18.86 | 19.91 | 19.56 | 18.39 | 17.49 | |
POCF ratio | 88.16 | 69.12 | 129.98 | 67.85 | 88.35 | |
PFCF ratio | 114.64 | 130.22 | 180.81 | 94.54 | 146.63 | |
P/B Ratio | 5.71 | 6.05 | 5.97 | 5.68 | 5.37 | |
PTB ratio | 5.71 | 6.05 | 5.97 | 5.68 | 5.37 | |
EV to sales | 20.92 | 22.23 | 21.68 | 20.45 | 19.38 | |
Enterprise value over EBITDA | 206.03 | 62.2 | 98.24 | 70.65 | 80.11 | |
EV to operating cash flow | 97.78 | 77.19 | 144.05 | 75.46 | 97.92 | |
EV to free cash flow | 127.15 | 145.42 | 200.38 | 105.14 | 162.52 | |
Earnings yield | 0 | 0.01 | 0.01 | 0.01 | 0 | |
Free cash flow yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Debt to equity | 0.79 | 0.88 | 0.8 | 0.77 | 0.73 | |
Debt to assets | 0.3 | 0.33 | 0.31 | 0.3 | 0.28 | |
Net debt to EBITDA | 20.27 | 6.5 | 9.6 | 7.13 | 7.83 | |
Current ratio | 0.86 | 0.9 | 0.87 | 0.79 | 0.82 | |
Interest coverage | -0.95 | 6.98 | 5.7 | 4.98 | 3.02 | |
Income quality | 3.08 | 1.39 | 0.82 | 1.88 | 2.65 | |
Dividend Yield | 0 | 0.01 | 0 | 0.01 | 0 | |
Payout ratio | 0 | 1.69 | 0.01 | 1.03 | 0 | |
Sales general and administrative to revenue | 0 | 0.37 | 0.44 | 0.42 | -1.15 | |
Research and developement to revenue | 0.23 | 0.24 | 0.23 | 0.22 | 0.26 | |
Intangibles to total assets | 0.61 | 0.61 | 0.6 | 0.6 | 0.57 | |
Capex to operating cash flow | -0.23 | -0.47 | -0.28 | -0.28 | -0.4 | |
Capex to revenue | -0.05 | -0.14 | -0.04 | -0.08 | -0.08 | |
Capex to depreciation | -0.37 | -0.98 | -0.38 | -0.69 | -1.08 | |
Stock based compensation to revenue | 0.06 | 0 | 0 | 0 | 0 | |
Graham number | 8.79 | 12.21 | 12.53 | 10.87 | 9.31 | |
ROIC | -0.01 | 0.03 | 0.03 | 0.02 | 0.02 | |
Return on tangible assets | 0.02 | 0.05 | 0.05 | 0.04 | 0.02 | |
Graham Net | -13.86 | -14.05 | -13.41 | -13.5 | -13.84 | |
Working capital | -3.7B | -2.59B | -3.54B | -6.09B | -5.49B | |
Tangible asset value | -22.07B | -23.48B | -20.87B | -20.41B | -18.97B | |
Net current asset value | -36.83B | -38.61B | -36.29B | -36.36B | -36.9B | |
Invested capital | 0.79 | 0.88 | 0.8 | 0.77 | 0.73 | |
Average receivables | 10.04B | 10.36B | 11.36B | 11.96B | 12.77B | |
Average payables | 18.37B | 19.13B | 19.47B | 20.14B | 11.9B | |
Average inventory | 4.89B | 4.83B | 5.01B | 5.17B | 5.36B | |
Days sales outstanding | 79.69 | 89.32 | 94.07 | 93.95 | 101.44 | |
Days payables outstanding | 590.9 | 907.56 | 906.34 | 882.47 | 127.4 | |
Days of inventory on hand | 145.83 | 234.66 | 231.93 | 227.34 | 211.51 | |
Receivables turnover | 1.13 | 1.01 | 0.96 | 0.96 | 0.89 | |
Payables turnover | 0.15 | 0.1 | 0.1 | 0.1 | 0.71 | |
Inventory turnover | 0.62 | 0.38 | 0.39 | 0.4 | 0.43 | |
ROE | 0.02 | 0.05 | 0.05 | 0.04 | 0.02 | |
Capex per share | -0.18 | -0.47 | -0.15 | -0.28 | -0.3 |
AZN Frequently Asked Questions
What is AstraZeneca PLC stock symbol ?
AstraZeneca PLC is a GB stock and trading under the symbol AZN
Is AstraZeneca PLC buy or a sell ?
4 stock analysts have 4 predictions with a medium analyst target price of $78.5. The lowest prediction is $75 and the highest is $82
What is AZN stock prediction ?
What is AstraZeneca PLC stock quote today ?
AstraZeneca PLC stock price is $68.26 today.
Is AstraZeneca PLC stock public?
Yes, AstraZeneca PLC is a publicly traded company.